Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
VTCN1 pseudogene 1 is a noncoding genetic element related to the VTCN1 gene, located on chromosome 20[5][7]. Pseudogenes arise from duplication or retrotransposition events and typically lack the ability to encode a functional protein. VTCN1P1 does not serve as a receptor, enzyme, or any type of molecular target in standard biological or pharmacological contexts, and has no documented functional or disease relevance[5]. Most biomedical research and therapeutic applications refer to the functional parent gene, **VTCN1 (V-set domain containing T cell activation inhibitor 1, also known as B7-H4, B7S1, B7X)**, which is an immune checkpoint molecule involved in modulating T cell activation and implicated in cancer progression[1][4][6][7][9][10]. There is no evidence supporting VTCN1P1 as a therapeutic target or biomarker. If structured information for a pharmacological target is needed, reference should be made to the functional **VTCN1 (B7-H4)** gene rather than its pseudogene VTCN1P1[1][4][6][7][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VTCN1 pseudogene 1 (VTCN1P1).